Compare Bath & Body Works Inc (BBWI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Bath & Body Works Inc trades at $18.46 (market cap $3.81B), while Vertex Pharmaceuticals Incorporated trades at $528.39 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 35.2× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 4.24% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| BBWI | VRTX | |
|---|---|---|
Market Cap | $3.81B | $134.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $529.65 |
52-Week Low | $14.85 | $376.62 |
Enterprise Value | $7.70B | $128.37B |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $19.32, down 5.11% over 24 hours, with a bearish technical signal and key support at $19. The stock shows attractive valuation metrics, including a P/E of 5.36 and P/S of 0.54, with a net income margin of 10.03% for 2025. Recent developments include expansion into Brazil and a partnership with Ulta Beauty, while Q2 2026 earnings are anticipated on August 26, 2026.
The outlook presents a value opportunity given low valuations and strategic growth initiatives, but risks include declining revenue trends, high debt levels, and negative shareholder equity. Analyst consensus is mixed with a $22.11 price target, suggesting potential upside if turnaround efforts succeed amidst competitive and execution challenges.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
